Abstract
Obesity in postmenopausal women is a risk factor for cardiovascular diseases. While estrogen is an essential hormone in regulating cardiometabolic parameters, especially concerning vascular and adipocyte function, estrogen as hormone therapy remains unsafe for all women. Recently, the use of semaglutide, a GLP-1 receptor agonist, has shown promising results in both weight loss and reducti…